Anti-human MxA antibody or antigen-binding portion thereof

Abstract

The present invention relates to the field of biotechnology, and in particular to anti-human MxA antibodies or antigen-binding portions thereof and applications thereof. Disclosed is a group of anti-human MxA antibodies or antigen-binding portions thereof that can be used in combination. The antibodies have stable performance and can avoid interference from other impurities. They can bind to MxA with high specificity, achieve high-affinity, high-sensitivity and high-precision measurement of MxA, and are of great significance to the research and development of auxiliary medical diagnostic reagents.

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to an anti-human MxA antibody or an antigen-binding portion thereof. Background Art

[0002] Myxovirus resistance protein A (MxA) is a protein produced by human cells that has the function of resisting viral infection. Studies have shown that MxA protein has the activity of resisting a variety of viruses. Many viruses infect the human body, such as influenza virus (Influenza virus), parainfluenza virus (PIV), adenovirus (ADV), herpes virus (Herpes virus), respiratory syncytial virus (RSV), Epstein-Barr virus, rhinovirus (RhV) and other viruses, which can induce human cells to produce MxA protein, while bacterial infection cannot induce high expression of MxA protein. In clinical practice, it is necessary to quickly distinguish between bacterial or viral infection to guide the direction of clinical treatment. Detecting the expression of human MxA protein can help quickly distinguish between viral infection and bacterial infection.

[0003] In emergency, rapid discrimination between viral and bacterial infections is of great value for timely and correct medication and thus saving lives. The sensitivity and linear width of detection in immunodiagnosis are often determined by the antibodies or antibody pairs used, so the specificity, sensitivity and linear width of the antibody are particularly important. At present, there are few MxA antibodies reported at home and abroad, and the effectiveness of these antibodies for clinical diagnosis has not been fully confirmed. Therefore, the development of antibodies with high recognition sensitivity for MxA proteins induced by viral infection of the human body has great clinical medical application value. Summary of the invention

[0004] The present invention provides two antibodies with high recognition reactivity to MxA protein, specifically as follows: an anti-human MxA antibody or an antigen-binding portion thereof, comprising:

[0005] (a) the heavy chain variable region CDR1 as set forth in SEQ ID NO.1; the heavy chain variable region CDR2 as set forth in SEQ ID NO.2; the heavy chain variable region CDR3 as set forth in SEQ ID NO.3; the light chain variable region CDR1 as set forth in SEQ ID NO.4; the light chain variable region CDR2 as set forth in SEQ ID NO.5; the light chain variable region CDR3 as set forth in SEQ ID NO.6;

[0006] or

[0007] (b) the heavy chain variable region CDR1 as listed in SEQ ID NO.7; the heavy chain variable region CDR2 as listed in SEQ ID NO.8; the heavy chain variable region CDR3 as listed in SEQ ID NO.9; the light chain variable region CDR1 as listed in SEQ ID NO.10; the light chain variable region CDR2 as listed in SEQ ID NO.11; the light chain variable region CDR3 as listed in SEQ ID NO.12.

[0008] Preferably, the anti-MxA antibody or antigen-binding portion thereof is a monoclonal antibody.

[0009] Preferably, the

[0010] The monoclonal antibody of (a) comprises a heavy chain variable region shown in SEQ ID NO: 13; and a light chain variable region shown in SEQ ID NO: 14;

[0011] (b) The monoclonal antibody comprises a heavy chain variable region as shown in SEQ ID NO: 15; and a light chain variable region as shown in SEQ ID NO: 16;

[0012] In another aspect, the present invention discloses a polynucleotide encoding the above-mentioned antibody or antigen-binding portion thereof.

[0013] The sequence of the nucleotide heavy chain variable region encoding the monoclonal antibody of (a) is shown in SEQ ID NO: 17, and the sequence of the light chain variable region is shown in SEQ ID NO: 18;

[0014] The sequence of the nucleotide heavy chain variable region encoding the monoclonal antibody of (b) is shown in SEQ ID NO: 19, and the sequence of the light chain variable region is shown in SEQ ID NO: 20;

[0015] In another aspect, the present invention discloses an antigen-antibody mixture, wherein the antigen-antibody mixture contains any one of the above-mentioned anti-human MxA antibodies or an antigen-binding portion thereof.

[0016] In another aspect, the present invention discloses a kit for detecting MxA, wherein the kit contains the anti-human MxA antibody or antigen-binding portion thereof or the antigen-antibody mixture as claimed in claim 1.

[0017] In another aspect, the present invention discloses a conjugate comprising the anti-human MxA antibody or antigen-binding portion thereof according to claim covalently linked to a chemical label or a biological label.

[0018] In another aspect, the present invention discloses a conjugate, wherein the conjugate is formed by coupling the anti-human MxA antibody or the antigen-binding portion thereof, and / or the conjugate with a solid medium or a semi-solid medium.

[0019] On the other hand, the present invention discloses the use of the anti-human MxA antibody or the antigen binding portion thereof and / or the conjugate and / or the conjugate in the preparation of a product for detecting MxA expression.

[0020] Beneficial Effects

[0021] The antibody sequence disclosed in the present invention has stable antibody performance and can achieve specific and efficient binding to MxA in a complex environment with many interfering factors in whole blood cell lysates. The human MxA immunochromatographic diagnostic reagent developed based on the antibody can achieve rapid identification of viral or bacterial infections and has important clinical practical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The interaction between the antibody disclosed in the present invention and the MxA protein;

[0023] Figure 2 Using the antibody of the present invention for MxA detection of clinical whole blood samples infected with parainfluenza virus (PIV);

[0024] Figure 3 Immunochromatographic reagent was used to detect the content of MxA protein in virus-infected samples. DETAILED DESCRIPTION

[0025] Example 1 Preparation of MxA Antibody

[0026] 1. Preparation of immunogen

[0027] The full-length human MxA protein (10-662Aa, P20591) was constructed into a eukaryotic expression vector to obtain an MxA expression plasmid. Serum-free acclimated 293 cells were suspended and cultured to a cell density of 2.0×10 6 The expression plasmid was transfected into 293 cells in suspension culture using PEI (polyethyleneimine)-mediated plasmid transfection method. After transfection, the culture was continued for 1 week, and the culture medium and feed were added at intervals. After the fermentation was completed, the cell pellet was collected by centrifugation at 4000g for 30min at 10℃. The cell pellet was resuspended in PBS and then broken by ultrasonic disruptor. After the cell wall was broken, the supernatant was collected by centrifugation for purification of the target protein.

[0028] 2. Mouse immunization and antibody detection

[0029] Select 5 6-8 week old SPF female BALB / c mice, mix and emulsify Freund's complete adjuvant and MxA protein at a concentration of 1 mg / ml in equal volumes. Use the emulsified antigen to immunize 6-8 week old SPF female BALB / c mice, and inject 40 μg of antigen protein into each mouse by foot injection. Two weeks after the first immunization, mix the antigen protein with Freund's incomplete adjuvant and emulsify it, and inject 40 μg of antigen protein into each mouse again by foot injection or back subcutaneous injection. Two weeks later, collect blood through the tail vein, collect the supernatant by centrifugation, and test the serum titer by ELISA. Immunize and test the serum titer every two weeks. After two immunizations, the serum titer is as high as 2.0 or above after a million-fold dilution. Screening serum titer 10 6 Lymph was taken from the above mice to separate lymphocytes for cell fusion.

[0030] 3. Hybridoma antibody screening

[0031] The antibody screening scheme is the key to the successful development of the antibodies of the present invention. In the antibody screening stage, the MxA protein is first labeled with biotin to obtain MxA-biotin. After the potential target antibody binds to MxA-biotin, avidin-HRP is used in combination with ELISA colorimetric solution to develop the color and screen out highly reactive hybridoma clones. Secondly, collect whole peripheral blood from patients diagnosed with viral infections such as PIV, RSV, ADV, and EBV as positive samples; collect whole peripheral blood from healthy people without the above viral infections as negative samples. The collected clinical samples are lysed for 10 minutes using 1% NP40 lysis solution (CA630) to obtain whole blood lysate. Use positive whole blood lysate to screen hybridoma clones with high reactivity to the sample, and use negative whole blood lysate to screen hybridoma clones with low reactivity to the sample.

[0032] The target clones screened need to meet the following conditions: 1. Good reactivity to recombinant MxA protein; 2. Good reactivity to positive whole blood lysate; 3. No obvious reactivity to negative whole blood lysate. The present invention screened MxA-A cell line and MxA-B cell line for the preparation of antibody A and antibody B.

[0033] 4. Production and purification of monoclonal antibodies

[0034] Two groups of 6-8 week old BALB / c mice were selected and injected intraperitoneally with 500 μL paraffin oil to suppress the immune response of mice. One week after the injection, 0.5 ml of MxA-A hybridoma cells were injected intraperitoneally into one group of mice, with a cell number of about 1×106; 0.5 ml of MxA-B hybridoma cells were injected intraperitoneally into the other group of mice. Ascites collection began two weeks later. The collected ascites was precipitated with ammonium sulfate and affinity purified with protein G to obtain the target antibody.

[0035] 5. Monoclonal antibody subtype identification and gene sequence cloning

[0036] The SBA Clonotyping System-HRP kit from Southern Biothech was used to identify the subtypes of the heavy and light chains of the monoclonal antibody according to the instructions. The specific procedures were as follows:

[0037] 1. Dilute the capture antibody to 1 μg / mL with coating solution (0.05M carbonate and bicarbonate buffer at pH 9.5), add 100 μL / well to the ELISA plate, and coat overnight at 4°C. Wash the plate three times with PBS buffer (washing solution) containing 0.05% Tween-20.

[0038] 2. Dilute the culture supernatant of the hybridoma cells to be tested with diluent (1% BSA, 0.1% PBST) at a ratio of 1:1, add 100 μL / well to the ELISA plate, and incubate at 37°C for 30 minutes. Dilute the corresponding enzyme-labeled antibodies (Ig-HRP, IgG1-HRP, IgG2a-HRP, IgG2b-HRP, IgG3-HRP, IgM-HRP, kappa-HRP, lamda-HRP) at a ratio of 1:3000 with diluent.

[0039] 3. After washing the plate three times with the plate washing solution, add 100 μL of diluted enzyme-labeled antibody to each well and incubate at 37°C for 30 minutes. After washing the plate three times again, add the color developing solution. After about 5 minutes (depending on the strength of the reaction), add 2M sulfuric acid to terminate the reaction and read the OD450 absorbance value. After identification, the heavy chain subtypes of MxA-A antibody and MxA-B antibody are both IgG1, and the light chain is Kappa. According to the antibody subtype results, the antibody gene sequence was cloned using a method based on the RACE technology route. Hybridoma cells with good growth status were collected, and the total RNA of the hybridoma cells was obtained using a total RNA extraction kit. According to the operating method of Takara's SMARTer RACE manual, the mRNA was reversely transcribed into cDNA, and the full-length sequence of the target antibody was amplified.

[0040] Example 2 Antibody Performance Verification

[0041] (1) Interaction between antibodies and MxA protein

[0042] This example verifies the binding performance of the antibody of the present invention through the interaction between the antibody and the MxA protein.

[0043] The specific operation steps are as follows: Antibody A / antibody B is diluted to 1ug / mL using coating solution (0.05M carbonate and bicarbonate buffer at pH 9.5) and coated on a conventional 96-well ELISA plate. The MxA protein purified after recombinant expression is biotinylated using a biotinylation reagent (finished commercial reagent). The biotin-modified MxA protein is diluted to each target concentration (20ng / μl, 40ng / μl, 60ng / μl,…,180ng / μl). Add a specific concentration of MxA protein to the ELISA wells coated with the target antibody, add 100μl to each well and incubate at 37°C for 30min. After washing the plate with a plate washing solution (150mM Nacl solution containing 0.05% Tween-20), add a 1:5000 diluted streptavidin-horseradish peroxidase conjugate (finished commercial reagent), add 100μl to each well and incubate at 37°C for 15min. Finally, the cells were incubated with ELISA colorimetric solution and the OD450 absorbance was detected using an enzyme-labeled instrument.

[0044] The results are as follows Figure 1 As shown in the figure, the experimental results of using enzyme-linked immunosorbent assay (ELISA) to detect the interaction between antibodies and recombinantly expressed and purified human MxA protein. The horizontal axis in the figure indicates the concentration of MxA protein used, and the vertical axis indicates the detection result of the ELISA experiment, that is, the absorbance value (OD450) detected by the spectrophotometer at 450nm. The higher the OD450 value, the stronger the detected interaction. The results show that the interaction between antibody A and antibody B is strong, and the antibody of the present invention is suitable for detecting MxA protein.

[0045] (2) Clinical validation

[0046] The specific operation is as follows: Antibody A is diluted to 1ug / mL using coating solution (0.05M carbonate and bicarbonate buffer at pH 9.5) and coated on a conventional 96-well ELISA plate. Each collected clinical sample is lysed with 1% NP-40, diluted 10 times with sample diluent (1% BSA, 0.1% Tween 20, 1X PBS) and added to the ELISA wells, and incubated at 37°C for 30min. Antibody B is labeled and coupled using horseradish peroxidase labeling reagent (finished commercial reagent) to prepare antibody B-HRP conjugate complex. Antibody B-HRP conjugate complex is diluted to 1ug / mL using diluent. After the ELISA wells incubated with samples are washed with plate washing solution (150mM Nacl solution containing 0.05% Tween-20), the diluted antibody B-HRP conjugate complex is added and incubated at 37°C for 30min. Finally, the cells were incubated with ELISA colorimetric solution and the OD450 absorbance was detected using an enzyme-labeled instrument.

[0047] The results are as follows Figure 2 As shown in the figure, the horizontal axis indicates different whole blood samples, and the vertical axis indicates the detection results obtained by the enzyme-linked immunosorbent assay (ELISA) experiment, that is, the absorbance value (OD450) detected by the spectrophotometer at 450nm. The higher the OD450 value, the stronger the detected interaction, indicating that the MxA protein concentration is higher. For the same sample, it has the same MxA protein concentration. The same MxA detection experiment is carried out using the antibody of the present invention or other anti-MxA antibodies. The OD value of the OD450 detection result of the antibody of the present invention is greater than 0.6, indicating that the antibody of the present invention has an excellent detection effect.

[0048] Example 3 Application of MxA Antibody in Immunochromatographic Detection

[0049] (1) Treatment of nitrocellulose membrane

[0050] a. Preparation of test line

[0051] Prepare 0.5 g / mL MxA antibody A with PBS, take 0.5 ul and draw a detection line in the middle of the nitrocellulose membrane.

[0052] b. Drying

[0053] Bake in a drying oven at 37°C for 2 h.

[0054] (2) Preparation of sample pad

[0055] Cut the glass cellulose membrane into strips of 20*30 cm each.

[0056] (3) Preparation of absorbent pad

[0057] Cut the absorbent paper into strips of 30*2.7cm each.

[0058] (4) Assembly

[0059] The plastic backing, sample pad and absorbent pad are common materials in the art, and the sample pad, nitrocellulose membrane and absorbent pad are tightly overlapped on the plastic backing at one time. The attached intermediate is cut into a 0.5 cm wide test strip using a chopper.

[0060] (5) How to use the test strips

[0061] a. Mix the sample to be tested and the antibody B-colloidal gold complex at a ratio of 4:1;

[0062] b. Add 60ul of the mixed solution to the sample well of the test strip prepared above;

[0063] c. The sample mixture is chromatographed until it binds to the MxA antibody A at the test line of the test strip.

[0064] (6) Kit performance verification

[0065] The experiment was carried out according to (5) above, and the results are as follows Figure 3 As shown in the figure, the arrow indicates that when the MxA protein is present in the test sample, the dark red colloidal gold aggregates appear at this position on the chromatography strip. The concentration of MxA protein in the sample is positively correlated with the aggregation degree of the colloidal gold at the arrow point (the color depth is positively correlated). The higher the concentration of MxA protein in the sample, the darker the color. The experimental results show that the MxA lateral flow immunochromatography reagent prepared using the antibody of the present invention has a good detection reaction effect on clinical samples. Sequence Listing <110> Chongqing Aisensi Bioengineering Co., Ltd. <120> Anti-human MxA antibody or antigen-binding portion thereof <130> 2022.6.8 <160> 20 <170> SIPOSequenceListing 1.0 <210> 1 <211> 5 <212> PRT <213> Synthetic <400> 1 Arg Ser Ala Met Asn 1 5 <210> 2 <211> 19 <212> PRT <213> Synthetic <400> 2 Arg Ile Arg Thr Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 3 <211> 6 <212> PRT <213> Synthetic <400> 3 Gly Ser Asp Phe Ala Tyr 1 5 <210> 4 <211> 11 <212> PRT <213> Synthetic <400> 4 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 5 <211> 7 <212> PRT <213> Synthetic <400> 5 Tyr Thr Ser Arg Leu Tyr Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Synthetic <400> 6 Gln Gln Gly Asn Thr Leu Pro Leu Thr 1 5 <210> 7 <211> 5 <212> PRT <213> Synthetic <400> 7 Ser Tyr Trp Ile Leu 1 5 <210> 8 <211> 17 <212> PRT <213> Synthetic <400> 8 Ala Val Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys 1 5 10 15 Gly <210> 9 <211> 8 <212> PRT <213> Synthetic <400> 9 Gly Tyr Asp Asn Ser Phe Asp Tyr 1 5 <210> 10 <211> 16 <212> PRT <213> Synthetic <400> 10 Arg Thr Ser Gln Thr Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 11 <211> 7 <212> PRT <213> Synthetic <400> 11 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 12 <211> 9 <212> PRT <213> Synthetic <400> 12 Phe Gln Gly Ser His Val Pro Pro Thr 1 5 <210> 13 <211> 117 <212> PRT <213> Synthetic <400> 13 Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Lys Gly 1 5 10 15 Ser Leu Ile Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Arg Ser 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Thr Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met 65 70 75 80 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 85 90 95 Tyr Cys Val Gly Gly Ser Asp Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ala 115 <210> 14 <211> 107 <212> PRT <213> Synthetic <400> 14 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Phe Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 15 <211> 117 <212> PRT <213> Synthetic <400> 15 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile Leu Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Val Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Asp Asn Ser Phe Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 16 <211> 112 <212> PRT <213> Synthetic <400> 16 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Thr Ser Gln Thr Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 17 <211> 351 <212> DNA <213> Synthetic <400> 17 gaggtgcagc ttgttgagac tggtggagga ttggtgcagc ctaaagggtc attgatagtt 60 tcatgtgcag cctctggatt caccttcaat agaagtgcca tgaactgggt ccgccaggct 120 ccaggaaagg gtttggaatg ggttgctcgc ataagaacta aaagtaataa ttatgcaaca 180 tattatgccg attcagtgaa agacaggttc accatctcca gagatgattc acaaagcatg 240 ctctatctgc aaatgaacaa cttgaaaact gaggacacag ccatgtatta ctgtgtaggg 300 ggtagcgatt ttgcttactg gggccaaggg actctggtca ctgtctctgc a 351 <210> 18 <211> 321 <212> DNA <213> Synthetic <400> 18 gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 attagttgca gggcaagtca ggacattagc aattatttaa actggtttca acagaaacca 120 gatggaactg ttaaactcct gatctactac acatcaagat tatattcagg agtcccatca 180 aggttcagtg gcagtgggtc tggaacagat tattctctca ccattaccaa cctggagcaa 240 gaagatattg ccacttactt ttgccaacag ggtaatacgc ttcctctcac gttcggtgct 300 gggaccaagc tggagctgaa a 321 <210> 19 <211> 351 <212> DNA <213> Synthetic <400> 19 caggttcagc tccagcagtc tggggctgag ctggcaagac ctggggcttc agtgaagttg 60 tcctgcaagg cttctggcta cacctttact tctttactgga tactgtggct aaaacagagg 120 cctggacagg gtctggaatg gattggggct gtttatcctg gagatggtga tactaggtac 180 actcagaagt tcaagggcaa ggccacattg actgcagata agtcctccag cactgcctac 240 atgcaactca gcagcttggc atctgaggac tctgcggtct attattgtgc aagaggctat 300 gataattcct ttgactactg gggccaagga accactctca cagtctcctc a 351 <210> 20 <211> 336 <212> DNA <213> Synthetic <400> 20 gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60 atctcttgca gaactagtca gaccattgta catagtaatg gaaacaccta tttagaatgg 120 tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180 tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240 agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc acatgttcct 300 cccacgttcg gtgctgggac caagctggag ctgaaa 336

Claims

1. An anti-human MxA antibody, characterized in that include: (a) the heavy chain variable region CDR1 as set forth in SEQ ID NO.1; the heavy chain variable region CDR2 as set forth in SEQ ID NO.2; the heavy chain variable region CDR3 as set forth in SEQ ID NO.3; the light chain variable region CDR1 as set forth in SEQ ID NO.4; the light chain variable region CDR2 as set forth in SEQ ID NO.5; the light chain variable region CDR3 as set forth in SEQ ID NO.6; or (b) the heavy chain variable region CDR1 as listed in SEQ ID NO.7; the heavy chain variable region CDR2 as listed in SEQ ID NO.8; the heavy chain variable region CDR3 as listed in SEQ ID NO.9; the light chain variable region CDR1 as listed in SEQ ID NO.10; the light chain variable region CDR2 as listed in SEQ ID NO.11; and the light chain variable region CDR3 as listed in SEQ ID NO.

12.

2. The anti-human MxA antibody according to claim 1, wherein The anti-MxA antibody is a monoclonal antibody.

3. The anti-human MxA antibody according to claim 2, characterized in that Said The monoclonal antibody of (a) comprises a heavy chain variable region shown in SEQ ID NO: 13; and a light chain variable region shown in SEQ ID NO: 14; The monoclonal antibody of (b) comprises a heavy chain variable region represented by SEQ ID NO: 15; and a light chain variable region represented by SEQ ID NO:

16.

4. A polynucleotide encoding the antibody according to any one of claims 1 to 3.

5. An antigen-antibody mixture, characterized in that: The antigen-antibody mixture contains the anti-human MxA antibody according to any one of claims 1 to 3.

6. A kit for detecting MxA, characterized in that: The kit contains the anti-human MxA antibody according to any one of claims 1 to 3 or the antigen-antibody mixture according to claim 5.

7. A combination, characterized in that The conjugate comprises the anti-human MxA antibody according to any one of claims 1 to 3 covalently linked to a chemical label or a biological label.

8. A conjugate, characterized in that: The conjugate is formed by coupling the anti-human MxA antibody described in any one of 1 to 3 and / or the conjugate described in claim 7 with a solid medium or a semi-solid medium.

9. Use of the anti-human MxA antibody according to any one of claims 1 to 3 and / or the conjugate according to claim 7 and / or the conjugate according to claim 8 in the preparation of a product for detecting MxA expression.

Images